This Is MS Multiple Sclerosis Knowledge & Support Community

Xenetic Biosciences has completed the Phase I, safety trial for its multiple sclerosis (MS) treatment MyeloXen and is now treating patients to establish dosing levels.

The Phase I trial passed without any adverse event on six healthy volunteers and its Russian partner, Pharmsynthez, has now started Phase II where 12 patients will receive escalating dosing levels to establish the safe dose level for MyeloXen...... Read More - http://www.ms-uk.org/index.cfm/MSnews

It appears to operate in a similar way to Copaxone, but is supposedly more effective in EAE. I wont be holding my breath for this one just yet.

http://en.pharmsynthez.com/Myeloxen.66.html

CureOrBust wrote:It appears to operate in a similar way to Copaxone, but is supposedly more effective in EAE. I wont be holding my breath for this one just yet.

http://en.pharmsynthez.com/Myeloxen.66.html

Have to agree with you on this one, Cure. More drugs to try and control the immune system of a MS patient when we don't even know the etiology of MS in the first place. But hey, the money to be made off MS with anything new that shows promise (marketing/sales strategy) can be quite rewarding.

Harry